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Safer drugs: Modifying immunogenicity 
in plant produced products 
Most bioproduction host systems lack the qualities for 
end product to be used in high-risk or high-throughput 
situations such as lifelong disorders, immune deficient 
individuals or the extremely young and old. 
 
 
Glycosylation is post-translational modification of products by sugar 
addition performed by host systems. Glycans are integral to the 
function and efficacy of the associated protein. Glycomodification 
requires addition of the relevant enzyme within the correct 
compartment of the Golgi, or removal of the endogenous enzyme.  
 
Core Fucose, Xylose and Lewis-a bodies are all epitopes of 
endogenous glycosylation conserved in most higher plants 
screened for use in therapeutics production. Each of these glycans 
are potentially immunogenic in humans. 
 
To “humanise” any plant product, hosts would require gene 
insertions of mammalian glycosylation enzymes, and genetic knock-
out of any endogenous enzymes producing sugars with 
immunogenic or off-target effects. 
 
 
Plants offer the potential of scalable, affordable, 
correctly-folded protein in a host innately tolerated 
across human applications,  without serious 
contamination threats 
 
Efficacy has been evidenced in production of virus-
like proteins (VLPs) for vaccine usage, and production 
of human enzyme replacement therapies. 
 
As plants are ubiquitously tolerated in our diets, 
advancements in gene technology have led to the 
potential of edible vaccines and drugs: 
pharmaceuticals expressed inside edible plant tissue 
that can deliver pharmacological efficacy orally. 
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Challenges 
• Specific human glycosylation is often essential for effective function and has serious effects on solubility, stability and elimination time 
• Plants do not have the endogenous mammalian glycosylation enzymes to achieve fully “humanized” proteins 
• Some endogenous plant glycans are considered unsafe for pharmaceutical applications, and may pose a barrier to use of plant products 
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Agrobacterium-mediated infiltration is a common means by 
which a genetic payload can be  delivered into mature plant 
tissues to produce transient alterations to gene expression.  
 
Depending on the design and sequence of the genetic 
cassette delivered, this can be the knock-in of new genetic 
material e.g. a mammalian enzyme, or the knock-out of 
existing genes, such as endogenous glycosylation enzymes. 
 
Transient infiltration of mature plants is an effective 
investigative tool, and a means to rapid production for a 
variety of responses. For example, the Zmapp Ebola vaccine 
was produced transiently in tobacco plants in response to 
the 2014 West Africa Ebola outbreak. The production cycle 
from genes, mature tobacco plant infiltration and 
harvesting of antibodies was complete in a few months, 
considerably shorter than existing production platforms. 
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o To explore expression of mammalian glycosylation enzymes transiently in a plant system as a means of humanising high 
value plant products 
o Reducing product immunogenicity to establish a plant system for safer drug manufacture 
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